Literature DB >> 16569378

Central nervous system infections in transplantation.

Todd Czartoski1.   

Abstract

Central nervous system (CNS) infections are a rare but serious complication of transplantation. An appropriate diagnostic workup should be streamlined with stratification of infection risk by length and degree of immune suppression, lesion localization, and timing. Polymerase chain reaction has high sensitivity and specificity for rapid identification of viral infections and should be used when available. Early diagnosis is imperative, and biopsy should be pursued if a diagnosis is not readily obtained with noninvasive testing. Treatment is pathogen specific. Combination antifungal therapy should be considered for cerebral aspergillosis. Zygomycetes and related invasive fungi require surgical resection and high-dose antifungal therapy. Viral meningoencephalitis therapy should be continued until resolution of clinical signs and symptoms, and viral clearance is verified with repeat cerebrospinal fluid analysis. Cytomegalovirus encephalitis requires ongoing maintenance therapy until clearance of viremia or antigenemia. Bacterial meningitis is uncommon in transplantation and should be treated with 21 days of antibiotics. CNS bacterial abscesses, including nocardiosis, should be surgically drained if feasible and treated until resolution of clinical and radiographic evidence of infection.

Entities:  

Year:  2006        PMID: 16569378     DOI: 10.1007/s11940-006-0010-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  47 in total

Review 1.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

Review 2.  Combination antifungal therapy: where are we now, and where are we going?

Authors:  Kieren Marr
Journal:  Oncology (Williston Park)       Date:  2004-11       Impact factor: 2.990

3.  Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study.

Authors:  Christian Junghanss; Kieren A Marr; Rachel A Carter; Brenda M Sandmaier; Michael B Maris; David G Maloney; Thomas Chauncey; Peter A McSweeney; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

4.  Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus.

Authors:  N Singh; D L Paterson
Journal:  Transplantation       Date:  2000-06-27       Impact factor: 4.939

5.  Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.

Authors:  A H Groll; N Giri; V Petraitis; R Petraitiene; M Candelario; J S Bacher; S C Piscitelli; T J Walsh
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

6.  Cerebral zygomycosis.

Authors:  C Sundaram; A Mahadevan; V Laxmi; T C Yasha; V Santosh; J M K Murthy; A K Purohit; S Mohandas; S K Shankar
Journal:  Mycoses       Date:  2005-11       Impact factor: 4.377

7.  Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient.

Authors:  J E Julin; J H van Burik; W Krivit; C Webb; C J Holman; H B Clark; H H Balfour
Journal:  Transpl Infect Dis       Date:  2002-12       Impact factor: 2.228

Review 8.  Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?

Authors:  Christian Junghanss; Kieren A Marr
Journal:  Curr Opin Infect Dis       Date:  2002-08       Impact factor: 4.915

9.  Two cases of cerebral aspergillosis successfully treated with voriconazole.

Authors:  V de Lastours; A Lefort; M Zappa; V Dufour; N Belmatoug; B Fantin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-10       Impact factor: 3.267

Review 10.  Update on the treatment of cerebral aspergillosis.

Authors:  S Schwartz; E Thiel
Journal:  Ann Hematol       Date:  2004       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.